---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-157303"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:43:51.025748+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Soleno expects Q2 2025 VYKAT XR net revenue of $31-33M; cash at $293.8M

## Summary
- Preliminary net revenue of VYKAT XR for Q2 2025: $31.0-$33.0 million.
- Cash, equivalents & marketable securities at June 30, 2025: ~$293.8 million.
- Received 646 patient start forms from ~295 unique prescribers since March 26, 2025 approval.
- Debt outstanding under Oxford Financing LLC loan: ~$50.0 million, unchanged.
- First revenue quarter for VYKAT XR; financial close and review ongoing.

## SEC filing metadata
- accession: 0001193125-25-157303
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312525157303/0001193125-25-157303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312525157303/d98442d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-157303
- JSON: https://secwatch.observer/filing/0001193125-25-157303.json
- Plain text: https://secwatch.observer/filing/0001193125-25-157303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.